Indian pharma major Zydus Cadila on Friday announced that it has received restricted emergency use approval from the Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN),  in treating  moderate coronavirus infection in adults.

"A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup," the company said in a filing.

"During the trials, a higher proportion of patients administered with PegIFN arm were  RT -PCR negative by day 7. The drug ensures faster viral clearance and has several add-on advantages compared to other anti-viral agents," the company said.

In a trial conducted in 20-25 centres across India, Zydus said Virafin had shown lesser need for supplemental oxygen, "clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating Covid-19."

Zydus said the drug has also shown efficacy against other viral infections.

Speaking on the development, Sharvil Patel, Managing Director of Cadila Healthcare said “The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against Covid-19.”

In its Phase-3 clinical trials, the therapy had shown better clinical improvement in the patients suffering from Covid-19.